$70 x 50M shares is $3.5B. That is nothing if Avid helps pphm go positive earnings, exsome kits go commercial, and pphm gets partnership for bavi. Not much at all.
The real issue is how many shares do they have to sell to raise money. How fast can they get Avid revenue to get to break even and how fast can they get a deal with exsomes with up front money or get the kits to market. Those two items will determine how many shares they will use to dilute us.
Quite frankly $70 x 70M shares is just $4.9B which is still nothing if the science can get monetized. That is 25M shares to dilute at $4+ per share or $100M to supplement their revenue from Avid. As long as they stick to their "no go it alone strategy" we can survive.
However, I am not convinced they will stick to it. They are greedy and have no skin in the game so why not go it alone?
News 
Market Data 
Discover 
